ClinicaliQ Trial Snapshot
- Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study — Recruiting • Phase IV • Rare Diseases • NCT07746895.
- What is being tested: Pegcetacoplan (a complement C3 inhibitor) effectiveness and safety in real-world clinical practice for patients with C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN), including assessment of non-routine biomarkers.
- Patient eligibility overview: The study includes patients with confirmed diagnoses of C3G or primary IC-MPGN across multiple countries, evaluating outcomes in routine clinical settings rather than controlled trial environments.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.
Eligibility Snapshot
- : * Have received or plan to receive pegcetacoplan for the treatment of C3G or primary IC-MPGN. * Provided signed and dated informed consent. For participants under the legal age signed and dated informed consent is provided by the participant's legally authorised representative. Assent will also be obtained from paediatric participants as required by local regulations.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.